Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

NCT02532400 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

21

Enrollment

OTHER

Sponsor class

Stopped Hard to enroll expected number of eligible patients.

Conditions

Breast Cancer

Interventions

DRUG: Neoadjuvant endocrine therapy
DRUG: Neoadjuvant chemotherapy

Sponsor

Ruijin Hospital